X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE DR. REDDYS LAB SUVEN LIFE/
DR. REDDYS LAB
 
P/E (TTM) x 19.2 29.1 65.8% View Chart
P/BV x 3.6 2.9 124.6% View Chart
Dividend Yield % 1.1 0.9 111.2%  

Financials

 SUVEN LIFE   DR. REDDYS LAB
EQUITY SHARE DATA
    SUVEN LIFE
Mar-16
DR. REDDYS LAB
Mar-17
SUVEN LIFE/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs3393,397 10.0%   
Low Rs1442,560 5.6%   
Sales per share (Unadj.) Rs39.2856.5 4.6%  
Earnings per share (Unadj.) Rs7.578.0 9.6%  
Cash flow per share (Unadj.) Rs8.8139.9 6.3%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.80.7 123.4%  
Book value per share (Unadj.) Rs49.0739.8 6.6%  
Shares outstanding (eoy) m127.28165.74 76.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x6.23.5 176.9%   
Avg P/E ratio x32.438.2 84.7%  
P/CF ratio (eoy) x27.521.3 129.2%  
Price / Book Value ratio x4.94.0 122.4%  
Dividend payout %26.825.7 104.5%   
Avg Mkt Cap Rs m30,732493,632 6.2%   
No. of employees `0001.022.7 4.2%   
Total wages/salary Rs m41631,068 1.3%   
Avg. sales/employee Rs Th5,236.16,259.0 83.7%   
Avg. wages/employee Rs Th436.51,369.8 31.9%   
Avg. net profit/employee Rs Th995.5569.7 174.7%   
INCOME DATA
Net Sales Rs m4,995141,961 3.5%  
Other income Rs m1941,715 11.3%   
Total revenues Rs m5,189143,676 3.6%   
Gross profit Rs m1,23324,722 5.0%  
Depreciation Rs m16710,266 1.6%   
Interest Rs m54634 8.5%   
Profit before tax Rs m1,20515,537 7.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2552,965 8.6%   
Profit after tax Rs m95012,921 7.4%  
Gross profit margin %24.717.4 141.7%  
Effective tax rate %21.219.1 110.9%   
Net profit margin %19.09.1 208.9%  
BALANCE SHEET DATA
Current assets Rs m4,98696,837 5.1%   
Current liabilities Rs m1,04284,199 1.2%   
Net working cap to sales %79.08.9 886.9%  
Current ratio x4.81.2 416.0%  
Inventory Days Days6173 83.1%  
Debtors Days Days3998 40.1%  
Net fixed assets Rs m3,126102,552 3.0%   
Share capital Rs m127829 15.4%   
"Free" reserves Rs m3,717121,792 3.1%   
Net worth Rs m6,236122,621 5.1%   
Long term debt Rs m4325,449 7.9%   
Total assets Rs m8,079218,165 3.7%  
Interest coverage x23.225.5 91.1%   
Debt to equity ratio x0.10 156.0%  
Sales to assets ratio x0.60.7 95.0%   
Return on assets %12.46.2 200.0%  
Return on equity %15.210.5 144.5%  
Return on capital %18.912.9 146.3%  
Exports to sales %87.554.6 160.2%   
Imports to sales %12.29.4 130.8%   
Exports (fob) Rs m4,37177,520 5.6%   
Imports (cif) Rs m61113,274 4.6%   
Fx inflow Rs m4,66681,670 5.7%   
Fx outflow Rs m94226,355 3.6%   
Net fx Rs m3,72455,315 6.7%   
CASH FLOW
From Operations Rs m92221,444 4.3%  
From Investments Rs m-619-18,404 3.4%  
From Financial Activity Rs m-698-3,692 18.9%  
Net Cashflow Rs m-396-1,144 34.6%  

Share Holding

Indian Promoters % 63.4 25.5 248.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 5.4 -  
FIIs % 0.0 35.3 -  
ADR/GDR % 0.0 18.5 -  
Free float % 36.5 15.3 238.6%  
Shareholders   37,287 75,885 49.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare SUVEN LIFE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Blueprint for Sensex 100,000(The 5 Minute Wrapup)

Feb 20, 2018

Investing in stocks is not about index gazing. There are 3-Ms that could help pick the right stocks.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Feb 23, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUVEN LIFE 8-QTR ANALYSIS

COMPARE SUVEN LIFE WITH

MARKET STATS